iX Biopharma Ltd. engages in the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. It operates through the Specialty Pharmaceutical and Nutraceutical segments. The Specialty Pharmaceutical segment develops, manufactures and sells pharmaceutical and nutraceutical products. The Nutraceutical segment offers nutraceutical products. The company was founded by Yip Hang Lee on May 8, 2004, and is headquartered in Singapore.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company